The short answer
Zepbound (tirzepatide) became the first GLP-1-class drug FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024).
Wegovy specifically
Off-label for OSA; on-label for obesity and cardiovascular risk reduction.
BMI & eligibility
The Zepbound OSA indication requires obesity. Other GLP-1s remain off-label for OSA and qualify through the obesity pathway (BMI ≥30, or ≥27 with comorbidity).
Check your BMI
BMI calculator
BMI 27-29.9 — eligible if comorbidity (T2D, hypertension, sleep apnea, PCOS).
BMI is one signal among several. Waist circumference, body composition, metabolic markers, and clinical history also matter — talk to a prescriber.
Insurance & coverage
Zepbound now has a direct OSA pathway — a sleep study confirming moderate-to-severe OSA plus obesity supports prior authorization. Other GLP-1s require an obesity-based PA.
Check if your plan covers itWe earn affiliate commissions from listed providers. See our editorial standards.
Other GLP-1s for obstructive sleep apnea
Wegovy for other conditions
Sources
- SURMOUNT-OSA trial — New England Journal of Medicine
- Zepbound prescribing information — FDA accessdata
Educational information, not medical advice. FDA-approval status reflects labeling as of 2026; off-label prescribing is legal and common but coverage varies.